Breast cancer+1
RecruitingStudy on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy
Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy
- Disease:Breast cancerHER2 positive breast cancer
- Substances:MolgramostimSargramostim
Austria- Participants:18–64 years · 65+ years
- Substances:Molgramostim
- Sponsor:Greenwich LifeSciences Inc.







